Picatoste et al. (2013) have shown that treatment of T2DM Goto-Kakizaki rats with sitagliptin (10 mg/kg/day) for 10 weeks promoted GLP-1-mediated cardioprotection primarily by limiting hyperglycaemia and hyperlipidemia [269]. The gene discussed is GLP1R; the disease is Hyperglycemia.